Summit Therapeutics, Inc. (SMMT)
14.16
0.00 (0.00%)
USD |
NASDAQ |
Sep 02, 11:30
Summit Therapeutics Research and Development Expense (Annual) : 537.67M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 537.67M |
| December 31, 2024 | 150.78M |
| December 31, 2023 | 59.47M |
| December 31, 2022 | 52.35M |
| December 31, 2021 | 84.34M |
| December 31, 2020 | 52.02M |
| December 31, 2019 | 41.99M |
| January 31, 2019 | |
| January 31, 2018 | 37.52M |
| January 31, 2017 | 25.25M |
| January 31, 2016 | 25.63M |
| January 31, 2015 | 17.01M |
| Date | Value |
|---|---|
| January 31, 2014 | 10.29M |
| January 31, 2013 | 5.756M |
| January 31, 2012 | 4.871M |
| January 31, 2011 | 3.568M |
| January 31, 2010 | 3.626M |
| January 31, 2009 | 9.138M |
| January 31, 2008 | 15.44M |
| January 31, 2007 | 5.480M |
| January 31, 2006 | 1.855M |
| January 31, 2005 | 0.4911M |
| January 31, 2004 | 0.0847M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 3.976M |
| Kezar Life Sciences, Inc. | 33.76M |
| Protara Therapeutics, Inc. | 42.49M |
| Clene, Inc. | 12.66M |